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1
H NMR and proton-decoupled 13 C NMR measurements were performed on Bruker Avance II 500 MHz spectrometer and Bruker Avance III HD 400 MHz spectrometer, using DMSO-d6 or CDCl 3 as solvent.
1 H and 13 C NMR data are in the form of delta values, given in parts per million (ppm) from tetramethylsilane (TMS), using the residual peak of the solvent as internal standard (DMSO-d6: 2.50 ppm (1 H)/39.5 ppm (13C); CDCl 3 : 7.26 ppm (1 H)/77.0 ppm (13C)). Splitting patterns are designated as: s (singlet), d (doublet), t (triplet), m (multiplet), br (broad singlet), dd (doublet of doublets). Due to the high level of conformational restriction of such structures (and specifically from StepA), chemical shifts are given as mentioned before when possible. Otherwise, they are expressed as ranges. HRMS were determined on a Waters QTOF2 or ORBITRAP VELOS PROTHERMO.
Synthesis of intermediate 1
Step 1.1: 1-formyl-2-piperidinecarboxylic acid A solution of racemic 2-piperidinecarboxylic acid (40 g, 0.310 mol) in formic acid (300 mL) was chilled to 0° C, and then acetic anhydride (200 mL, 2.15 mol) was added dropwise. The reaction was stirred at room temperature overnight and then cooled to 0° C, quenched by water (250 mL) and stirred for 30 minutes at 0° C before being concentrated to dryness. The oil obtained was taken up in methanol (200 mL) and then concentrated to dryness again, giving 1-Formyl-2-piperidinecarboxylic acid as colorless oil (47.6 g, 0.303 mol, 98%). 
Step 1.2: Methyl 5,6,7,8-tetrahydro-1-indolizinecarboxylate
To a solution of 1-formyl-2-piperidinecarboxylic acid (10 g, 63.6 mmol) in dichloroethane (65 mL) was added tosyl chloride (13.4 g, 70.4 mmol), methyl 2-chloroacrylate (11.5 mL, 113.5 mmol) and then dropwise, N,N,N-triethylamine (17.8 mL, 127.2 mmol). The reaction mixture was heated to reflux for 1.5 hours, cooled down to room temperature and methyl 2-chloroacrylate (5 mL, 48.9 mmol) and N,N,N-triethylamine (9 mL, 64 mmol) were added. The resultant mixture was heated to reflux overnight, diluted with methylene chloride, washed with a 1N HCl solution, saturated NaHCO 3 solution and brine. The organic phase was dried over MgSO 4 , filtered, and concentrated to dryness. The residue was purified by flash chromatography (heptane/EtOAc gradient) to give Methyl 5, 6, 7, Step 1.3: Methyl 3-(6-formyl-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydro-1-indolizine-carboxylate
To a solution of methyl 5,6,7,8-tetrahydro-1-indolizinecarboxylate (6.4 g, 35.7 mmol) in N,Ndimethylacetamide (12 mL) was added 6-bromo-1,3-benzodioxole-5-carbaldehyde (12.3 g, 53.6 mmol) and potassium acetate (7 g, 71.4 mmol). The reaction mixture was degassed over 20 min by bubbling a stream of argon. Bis(triphenylphosphine)palladium(II) dichloride (1.3 g, 1.8 mmol) was added and the reaction mixture was heated at 130° C for one hour and water (139 µL) was added. Heating was maintained at that same temperature overnight. The resultant mixture was diluted with AcOEt, activated charcoal (12 g) was added and the mixture was stirred for one hour and filtered. The resulting organic phase was washed with water, dried over MgSO 4 and concentrated to dryness. The residue was purified by flash chromatography (heptane/EtOAc gradient) to give methyl 3-(6-formyl-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydro-1-indolizinecarboxylate (7 g, 70%) as a colorless oil. To a solution of (3S)-2-[(benzyloxy)carbonyl]-1,2,3, 4-tetrahydro-3-isoquinolinecarboxylic acid (5 g, 16 mmol) in dichloromethane (160 mL) was added morpholine (1.5 mL, 17.6 mmol), N,N,N-triethylamine (9 mL, 64 mmol), N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydroch loride (3.3 g, 19.2 mmol) and hydroxybenzotriazole (2.6 g, 19.2 mmol). The reaction mixture was stirred at room temperature overnight, poured into an saturated aqueous solution of ammonium chloride and extracted with ethyl acetate. The combined organic layers were dried over MgSO 4 , filtered and evaporated to dryness.
The residue was purified by flash chromatography (dichloromethane/methanol gradient) to give benzyl (3S)-3-(4-morpholinylcarbonyl)-3,4-dihydro-2(1H)-isoquinoline carboxylate (5.3 g, 87%) as a white solid. Step
2.2: Benzyl (3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinoline carboxylate
To a solution of benzyl (3S)-3-(4-morpholinylcarbonyl)-3,4-dihydro-2(1H)-isoquinoline carboxylate (5.3 g, 13.9 mmol) in THF (278 mL) was added a 2M solution of BH 3 Me 2 S (14 mL, 27.8 mmol) in THF at room temperature. The reaction mixture was heated for 4 hours at 80° C, cooled down to room temperature, BH 3 Me 2 S 2 M in THF was added again (7 mL, 14 mmol). The reaction mixture was again heated at 80° C for 2 hours and concentrated under reduced pressure and slowly diluted with methanol (20 mL) and 5N hydrochloric acid (5.6 mL, 27.8 mmol). The mixture was stirred at room temperature overnight and for one hour at 80° C. The resultant mixture was neutralized carefully adding saturated NaHCO 3 solution at 0° C until pH 8 and extracted with AcOEt. The combined organic layers were dried over MgSO 4 , filtrered and evaporated to dryness, giving crude benzyl (3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinoline carboxylate (4.9 g, 96%) as a colorless oil that was used without further purification in the next step. Step
2.3: (3S)-3-(4-Morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline
To a solution of benzyl (3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinoline carboxylate (4.9 g, 13.4 mmol) in ethanol (67 mL) was added palladium hydroxide on charcoal (20% Pd w/w, 0.980 g). The reaction mixture was stirred under H 2 atmosphere (1.2 bar) at room temperature for 4 hours, filtered and the filtrate was evaporated to dryness, affording (3S)-3-(4-Morpholinylmethyl)-1,2,3,4-tetrahydroisoquinoline (2.95 g, 95%) as a colorless oil. Final steps:
Step 
Step C: N-[4-[tert-Butyl(dimethyl)silyl] oxyphenyl]-3-[6-[(3S)-3-(morpholinomethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide
To a 0° C solution of 3-[6-(3-morpholin-4-yl methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl)-benzo[1, 3]dioxo-5-yl]-5,6,7,8-tetrahydro-indolizine-1-lithium carb oxylate (2.6 g, 4.73 mmol) in dichloromethane (47 mL) was added dropwise oxalyl chloride (1.2 mL, 14.1 mmol). After stirring at room temperature for 11 hours, the reaction mixture was evaporated under reduced pressure. The residue was dissolved in dichloromethane (10 mL) and evaporated to dryness. This was repeated two times and then the residue was diluted with dichloromethane (37 mL) and a solution of 4-[(tert-butyldimethylsilyl) oxy]-N-phenylaniline (2.1g, 7.1mmol) and pyridine (0.6 mL, 7.1 mmol) in dichloromethane (10 mL) was added. The reaction mixture was stirred at room temperature overnight, concentrated under reduced pressure and purified by flash column chromatography on silica -phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide (1.9 g, 2. 3 mmol) in methanol (4 mL) was added a solution of potassium hydroxide (0.646 g , 11.5 mmol) in methanol (8 mL). The reaction mixture was stirred for 30 minutes at room temperature, diluted with dichloromethane, washed successively with 1N HCl solution, saturated NaHCO 3 solution and brine. The organic phase was dried over MgSO 4 , filtered and concentrated in vacuo. The residue was purified by flash chromatography on
,7,8-tetrahydroindolizine-1-carboxamide (1.3 g, 1.9 mmol) as a white solid.
The corresponding hydrochloride salt was obtained by diluting the free base in dichloromethane and addition of a solution of 1 M HCl in ether (2 mL, 2 mmol), after 1h evaporation to dryness, solubilization in MeCN/H 2 O and freeze-drying, affording N-(4-hydroxyphenyl)-3-[6-[(3S)-3-(morpholinomethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride (1.37 g, 1.8 mmol) as a white solid. 
13
C NMR 13C (500 MHz, dmso-d6) δ ppm 130-123, 129, 115.6, 110.1, 110, 107.8, 101.6, 62.8, 55.4, 52.5/50.3, 44.6, 43.7, 41.3, 30.7, 24.1, 22.1, 19. Optical rotation: (α) D 20 = + 50.8° cm 3 g −1 dm −1 (c = 9 mg/ml in MeOH) Chiral purity: Purity >99% (SFC, using Cellocoat 3µm 4.6 × 150 mm column, eluent: CO 2 /(methanol/ diethylamine: 100/0.5): 70/30), by comparison with the R enantiomer.
Cell line culture
All cell lines were grown at 37° C in a humidified atmosphere with 5% CO 2 ® TIB-202™) were purchased from American Type Culture Collection (ATCC). OCI-LY18, Mino, U2932, NUDHL-1, OCI-LY3, BL-2, OCI-LY19, OCI-LY7, OCI-LY1 were from Leibniz-Institute DSMZ (Braunschweig, Germany). RS4;11 and THP-1 cells were cultured in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 mM Hepes, pH 7.4. The medium was supplemented with 4.5 g/L glucose. HeLa cells were cultured in DMEM medium (containing 10% heat inactivated FBS, 10 mM Hepes, 100 U/mL penicillin, 100 µg/ml streptomycin). Pfeiffer, OCI-LY18, Toledo, U2932, NUDHL-1, SUDHL-6, DB, REC-1, JVM-2, H146, Daudi, Raji and Ramos cells were cultured in RPMI 1640 medium supplemented with 10% heat inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ ml streptomycin, and 10 mM Hepes, pH 7.4. OCI-LY3, BL-2 and Jeko cells were cultured in the same medium supplemented with 20% FBS. Mino were cultured in the same medium supplemented with 15% FBS. OCI-LY19 cells were cultured in Alpha MEM medium supplemented with 10% heat inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 mM Hepes, pH 7.4. OCI-LY7 and Z-138 cells were cultured in IMDM medium supplemented with 10% heat inactivated FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ ml streptomycin, and 10 mM Hepes, pH 7.4. OCI-LY1 were cultured in the same medium supplemented with 20% FBS. Media and supplements were purchased from Life Technologies except FBS, which was purchased from Sigma Chemical, Co. All cell lines were routinely screened for mycoplasma every month using MycoAlert (Lonza) and authentified using PCR-single-locustechnology (Eurofins). Cell lines were not grown more than 20 passages.
FL5.12 cells overexpressing BCL-2 or BCL-XL were kindly provided by Drs. A. Letai and L. Boise, respectively and cultured in RPMI 1640 supplemented with 10% Fetal Calf Serum, 2 mM L-glutamine and 10% of IL3-containing WEHI-3 cell culture supernatant. To assess sensitivity to BCL-2 inhibitors, FL5.12 cells were cultured for 24 h in the absence of IL-3 before treatment with BCL-2-inhibitors for an additional 24 h.
THP-1 knock-out BAX/BAK generation
For each round of transduction, lentiviral particles (Sigma Aldrich) were used to transduce 2 × 10 5 cells with a multiplicity of infection (MOI) of 10 for 2 h at 32° C in the presence of 8 µg/ml of polybrene. The virus-containing medium was then replaced with fresh medium and cells were incubated at 37° C for 48 h/72 h before starting selection.
THP-1 cells were first transduced with EF1a-Cas9-2A Neomycin (Sigma Aldrich). 96 h after transduction cells were put under neomycin selection (800 µg/ml, Invitrogen) for 10 days before being sorted as single-cells for the isolation of clones. One clone was then further transduced with pLV-U6g-EGFP-gRNA BAK1 (Sigma Aldrich, gRNA sequence: 5′ GCATGAAGTCGACCACGAAG 3′). 48 h after transduction cells were sorted as single-cells based on the expression of the GFP reporter gene. Cells were then further transduced with pLV-U6g-Puromycin gRNA BAX (Sigma Aldrich, gRNA sequence: 5′ CTGC AGGATGATTGCCGCCG 3′). 96 h after transduction cells were put under puromycin selection (1 µg/ml) for 9 days before being sorted as single-cells for the isolation of clones. BAX and BAK knock-out efficiency on different clones was verified by Western blot.
shRNA lentiviral transduction
Cleaved PARP and cleaved caspase-3 immunodetection by MesoScale Discovery (MSD) assay 24 h after seeding, cells were treated with the indicated compounds for 4 h and harvested in lysis buffer (10 mM Hepes pH 7.4, 142.5 mM KCl, 5 mM MgCl 2 , 1 mM EDTA, 1% NP40), protease and phosphatase inhibitors cocktails (Calbiochem 539134 and 524625)).
Cleared lysates (5 µg) were assayed for immunodetection of cleaved PARP and cleaved caspase-3 with MSD Apoptosis Panel Whole Cell Lysate kit (MSD K15102D) in 96-well plates according to manufacturer's instructions, and analyzed on the Sector Image 2400. Control DMSO conditions were set to 100% and fold-activation calculated. For ex vivo experiments, once corrected with the blank, data from treated groups were represented as mean of the fold-increase compared to untreated control group. 
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